Bullous Sweet Syndrome As a Presentation of Chronic Myelogenous Leukaemia

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2022 Dec 1

PMID 36455980

Authors

Syeda Wajiha Abbas

Zarnain Shah

Mohammad Usman Shaikh

Affiliations

Soon will be listed here.

Abstract

A woman in her 40s presented with a 3-month-long history of fever and tender erythematous bullous skin lesions not responsive to antibiotics. There had been no previous gastrointestinal, respiratory or urinary infection, nor did she have any history of autoimmune disease, drug reaction or vasculitis.Histological evaluation of skin biopsy showed diffuse dense neutrophilic infiltrates located in dermis diagnostic of Sweet syndrome. Haematological investigations showed leucocytosis with circulating immature cells, which on further investigations with bone marrow biopsy, were evident of chronic myelogenous leukaemia in the accelerated phase. Sweet syndrome was the presenting characteristic of chronic myelogenous leukaemia in this case, which is a rare association. Investigating unusual skin lesions can aid in the suspicion of underlying cancer, allowing for prompt action.

References

Larson A, Granter S . Systemic lupus erythematosus-associated neutrophilic dermatosis--an underrecognized neutrophilic dermatosis in patients with systemic lupus erythematosus. Hum Pathol. 2014; 45(3):598-605. DOI: 10.1016/j.humpath.2013.10.029. View

Cohen P, Holder W, Tucker S, Kono S, Kurzrock R . Sweet syndrome in patients with solid tumors. Cancer. 1993; 72(9):2723-31. DOI: 10.1002/1097-0142(19931101)72:9<2723::aid-cncr2820720933>3.0.co;2-f. View

Wick M, Patterson J . Cutaneous paraneoplastic syndromes. Semin Diagn Pathol. 2019; 36(4):211-228. DOI: 10.1053/j.semdp.2019.01.001. View

Gilmour E, Chalmers R, Rowlands D . Drug-induced Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with hydralazine. Br J Dermatol. 1995; 133(3):490-1. DOI: 10.1111/j.1365-2133.1995.tb02686.x. View

Bhat A, Siddappa Malleshappa S, Pasupula D, Duke W, Shaaban R . Bullous Variant of Sweet's Syndrome as a Consequence of Radioiodine Contrast Exposure. Cureus. 2019; 10(10):e3490. PMC: 6318143. DOI: 10.7759/cureus.3490. View

Smolovic B, Gajic-Veljic M, Nikolic M, Muhovic D . Pregnancy-Induced Sweet's Syndrome Treated with Infliximab. Med Princ Pract. 2018; 28(2):196-198. PMC: 6545913. DOI: 10.1159/000494974. View

Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L . Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2014; 26(1):185-192. DOI: 10.1093/annonc/mdu490. View

Cohen P, Kurzrock R . Sweet's syndrome and cancer. Clin Dermatol. 1993; 11(1):149-57. DOI: 10.1016/0738-081x(93)90112-p. View

Draper B, Robbins J, Robbins J, Stricklin G . Bullous Sweet's syndrome in congenital neutropenia: association with pegfilgrastim. J Am Acad Dermatol. 2005; 52(5):901-5. DOI: 10.1016/j.jaad.2004.12.028. View

10.

Cohen P . Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007; 2:34. PMC: 1963326. DOI: 10.1186/1750-1172-2-34. View

11.

Ayirookuzhi S, Ma L, Ramshesh P, Mills G . Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia. Arch Dermatol. 2005; 141(3):368-70. DOI: 10.1001/archderm.141.3.368. View

12.

Heath M, Ortega-Loayza A . Insights Into the Pathogenesis of Sweet's Syndrome. Front Immunol. 2019; 10:414. PMC: 6424218. DOI: 10.3389/fimmu.2019.00414. View